Results 181 to 190 of about 18,286 (260)

Evaluation of Moderate-Course Hydrocortisone for the Prevention of Bronchopulmonary Dysplasia in Premature Infants: A Pilot Study. [PDF]

J Pediatr Pharmacol Ther
Sical C, Hernandez M, Galura G.
europepmc   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, Volume 104, Issue 5, Page e565-e577, August 2026.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

Editorial: Responses to chronic stress in vertebrate animals: from molecules to behavior. [PDF]

Front Endocrinol (Lausanne)
Samaras A, Raftogianni A, Gorissen M.
europepmc   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

A detailed review of pharmacokinetics/pharmacodynamics of progestogens in oral contraception. [PDF]

Front Endocrinol (Lausanne)
Gaspard U, Chatel G, Douxfils J, Stanczyk FZ.   +3 more
europepmc   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7416-7429, August 2026.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

A Case of Concurrent Autoimmune Thyroiditis and Adrenal Insufficiency Following Nivolumab Therapy for Advanced Renal Cell Carcinoma. [PDF]

Cureus
Dooley GD, Li H, Agomuoh I, Al-Saghir F, Arsene C.   +4 more
europepmc   +1 more source

Early Hemolysis, Myolysis and Renal Stress Following Pentaspline Pulsed Field Versus Radiofrequency Ablation of Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.
Serial biomarker assessment in 40 patients undergoing first‐time pulmonary vein isolation showed greater hemolysis and myocardial myolysis after FARAPULSE pentaspline single‐shot pulsed field ablation than after radiofrequency ablation. Myoglobin changes were associated with transient changes in renal function, albeit these exploratory correlations do ...
Paul Felix Harbich, Lisa Auer, Florian Tinhofer, Achim Leo Burger, Tobias Eberl, Patrick Weltler, Stephan Dobner, Alexander Geppert, Kurt Huber, Christoph Clemens Kaufmann   +9 more
wiley   +1 more source

Finrenone and sodium-glucose cotransporter 2 inhibitor polypill: how "CONFIDENT" are we? [PDF]

Kidney Res Clin Pract
Mathew GG.
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, Volume 56, Issue 8, Page 1225-1234, August 2026.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source